These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 27723281)

  • 21. Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study.
    McBride JM; Jiang J; Abbas AR; Morimoto A; Li J; Maciuca R; Townsend M; Wallace DJ; Kennedy WP; Drappa J
    Arthritis Rheum; 2012 Nov; 64(11):3666-76. PubMed ID: 22833362
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: findings of a prospective, randomized, double-blind, placebo-controlled trial.
    Tseng CE; Buyon JP; Kim M; Belmont HM; Mackay M; Diamond B; Marder G; Rosenthal P; Haines K; Ilie V; Abramson SB
    Arthritis Rheum; 2006 Nov; 54(11):3623-32. PubMed ID: 17075807
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Baseline autoantibody profiles predict normalization of complement and anti-dsDNA autoantibody levels following rituximab treatment in systemic lupus erythematosus.
    Tew GW; Rabbee N; Wolslegel K; Hsieh HJ; Monroe JG; Behrens TW; Brunetta PG; Keir ME
    Lupus; 2010 Feb; 19(2):146-57. PubMed ID: 19946034
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of systemic lupus erythematosus patients with the BAFF antagonist "peptibody" blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials.
    Stohl W; Merrill JT; Looney RJ; Buyon J; Wallace DJ; Weisman MH; Ginzler EM; Cooke B; Holloway D; Kaliyaperumal A; Kuchimanchi KR; Cheah TC; Rasmussen E; Ferbas J; Belouski SS; Tsuji W; Zack DJ
    Arthritis Res Ther; 2015 Aug; 17(1):215. PubMed ID: 26290435
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Belimumab, a BLyS-specific inhibitor for the treatment of systemic lupus erythematosus.
    Espinosa G; Cervera R
    Drugs Today (Barc); 2010 Dec; 46(12):891-9. PubMed ID: 21589946
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-interferon alpha treatment in SLE.
    Kirou KA; Gkrouzman E
    Clin Immunol; 2013 Sep; 148(3):303-12. PubMed ID: 23566912
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic targeting of the BAFF/APRIL axis in systemic lupus erythematosus.
    Stohl W
    Expert Opin Ther Targets; 2014 Apr; 18(4):473-89. PubMed ID: 24521424
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and Tolerability of Omalizumab: A Randomized Clinical Trial of Humanized Anti-IgE Monoclonal Antibody in Systemic Lupus Erythematosus.
    Hasni S; Gupta S; Davis M; Poncio E; Temesgen-Oyelakin Y; Joyal E; Fike A; Manna Z; Auh S; Shi Y; Chan D; Carlucci P; Biehl A; Dema B; Charles N; Balow JE; Waldman M; Siegel RM; Kaplan MJ; Rivera J
    Arthritis Rheumatol; 2019 Jul; 71(7):1135-1140. PubMed ID: 30597768
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus.
    Feng X; Wu H; Grossman JM; Hanvivadhanakul P; FitzGerald JD; Park GS; Dong X; Chen W; Kim MH; Weng HH; Furst DE; Gorn A; McMahon M; Taylor M; Brahn E; Hahn BH; Tsao BP
    Arthritis Rheum; 2006 Sep; 54(9):2951-62. PubMed ID: 16947629
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel signatures associated with systemic lupus erythematosus clinical response to IFN-α/-ω inhibition.
    Seridi L; Cesaroni M; Orillion A; Schreiter J; Chevrier M; Marciniak S; Migone TS; Stohl W; Chatham WW; Furie RA; Benson J; Jordan J
    Lupus; 2021 Apr; 30(5):795-806. PubMed ID: 33626969
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lack of association between the interferon-alpha signature and longitudinal changes in disease activity in systemic lupus erythematosus.
    Landolt-Marticorena C; Bonventi G; Lubovich A; Ferguson C; Unnithan T; Su J; Gladman DD; Urowitz M; Fortin PR; Wither J
    Ann Rheum Dis; 2009 Sep; 68(9):1440-6. PubMed ID: 18772188
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Spotlight on anifrolumab and its potential for the treatment of moderate-to-severe systemic lupus erythematosus: evidence to date.
    Felten R; Scher F; Sagez F; Chasset F; Arnaud L
    Drug Des Devel Ther; 2019; 13():1535-1543. PubMed ID: 31190735
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus.
    Szepietowski JC; Nilganuwong S; Wozniacka A; Kuhn A; Nyberg F; van Vollenhoven RF; Bengtsson AA; Reich A; de Vries DE; van Hartingsveldt B; Robinson DW; Gordon R; Hsu B
    Arthritis Rheum; 2013 Oct; 65(10):2661-71. PubMed ID: 23896980
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of tabalumab, an anti-B-cell-activating factor monoclonal antibody, in patients with rheumatoid arthritis who had an inadequate response to methotrexate therapy: results from a phase III multicentre, randomised, double-blind study.
    Smolen JS; Weinblatt ME; van der Heijde D; Rigby WF; van Vollenhoven R; Bingham CO; Veenhuizen M; Gill A; Zhao F; Komocsar WJ; Berclaz PY; Ortmann R; Lee C
    Ann Rheum Dis; 2015 Aug; 74(8):1567-70. PubMed ID: 25873635
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trials.
    Baker T; Sharifian H; Newcombe PJ; Gavin PG; Lazarus MN; Ramaswamy M; White WI; Ferrari N; Muthas D; Tummala R; Morand EF; Furie RA; Vital EM; Chamberlain C; Platt A; Al-Mossawi H; Brohawn PZ; Csomor E
    Ann Rheum Dis; 2024 Jul; 83(8):1018-1027. PubMed ID: 38569851
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Repeated administration of dapirolizumab pegol in a randomised phase I study is well tolerated and accompanied by improvements in several composite measures of systemic lupus erythematosus disease activity and changes in whole blood transcriptomic profiles.
    Chamberlain C; Colman PJ; Ranger AM; Burkly LC; Johnston GI; Otoul C; Stach C; Zamacona M; Dörner T; Urowitz M; Hiepe F
    Ann Rheum Dis; 2017 Nov; 76(11):1837-1844. PubMed ID: 28780512
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease.
    Kirou KA; Lee C; George S; Louca K; Peterson MG; Crow MK
    Arthritis Rheum; 2005 May; 52(5):1491-503. PubMed ID: 15880830
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interferon α kinoid induces neutralizing anti-interferon α antibodies that decrease the expression of interferon-induced and B cell activation associated transcripts: analysis of extended follow-up data from the interferon α kinoid phase I/II study.
    Ducreux J; Houssiau FA; Vandepapelière P; Jorgensen C; Lazaro E; Spertini F; Colaone F; Roucairol C; Laborie M; Croughs T; Grouard-Vogel G; Lauwerys BR
    Rheumatology (Oxford); 2016 Oct; 55(10):1901-5. PubMed ID: 27354683
    [TBL] [Abstract][Full Text] [Related]  

  • 39. B-cell-targeted therapy for systemic lupus erythematosus.
    Sabahi R; Anolik JH
    Drugs; 2006; 66(15):1933-48. PubMed ID: 17100405
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE).
    Kalunian KC; Merrill JT; Maciuca R; McBride JM; Townsend MJ; Wei X; Davis JC; Kennedy WP
    Ann Rheum Dis; 2016 Jan; 75(1):196-202. PubMed ID: 26038091
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.